Novo Nordisk A/s Class B · OMXCOP:NOVO_B
Novo Nordisk A/s Class B — Investor Day (March 2024)
24 slides from Novo Nordisk A/s Class B's investor day presentation, Mar 7, 2024
Slide 1: Obesity care
Novo Nordisk® Obesity care Camilla Sylvest EVP Commercial Strategy and Corporate Affairs Doug Langa EVP North America Operations Mike Doustdar EVP International Operations 7 MARCH Martin Holst Lange EVP Development ABIGAIL CONIAH Abigail lives with obesity United Kingdom
Slide 2: Forward-looking statements
2 Obesity care Commercial execution and innovation Novo Nordisk® Forward-looking statements Novo Nordisk’s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including the statutory Annual Report 2023 and Form 20-F, which both were filed with the SEC in January 2024
Slide 3: Strategic aspirations 2025
3 Obesity care Commercial execution and innovation Novo Nordisk® Strategic aspirations 2025 • Further raise the innovation-bar for diabetes treatment therapeutic focus • Progress towards zero environmental impact • Develop a leading portfolio of superior treatment Innovation and solutions for obesit
Slide 4: Obesity is a serious chronic disease with a large unmet medical need
4 Obesity care Commercial execution and innovation Novo Nordisk® Obesity is a serious chronic disease with a large unmet medical need that impacts many aspects of a patient's life Large and increasing unmet need in obesity Obesity is associated with complications Life expectancy decreases as BMI inc
Slide 5: Semaglutide 2.4 mg impact on comorbidities that overlap with obesity
5 Obesity care Commercial execution and innovation Novo Nordisk® In clinical trials, semaglutide 2.4 mg has demonstrated an impact on comorbidities that overlap with obesity Weight loss Disease overlap in the United States Obesity-related comorbidities UNITED STATES ONLY REDEFINE (CagriSema) SELECT
Slide 6: In SELECT, semaglutide 2.4 mg reduced risk of a broad composite endpoint by 37%
6 Obesity care Commercial execution and innovation Novo Nordisk® In SELECT, semaglutide 2.4 mg reduced the risk of a broad composite endpoint by 37% Key results of the SELECT trial Risk reduction in broad composite endpoint 20% Cardiovascular risk reduction in 3-point MACE Semaglutide 2.4 mg reduces
Slide 7: Consistent reductions in heart failure endpoints in pooled SELECT and STEP-HFpEF data
7 Obesity care Commercial execution and innovation Novo Nordisk® Consistent reductions in heart failure endpoints shown in pooled data from the SELECT and STEP-HFpEF trials Time-to-event for Hospitalisation for heart failure Time-to-event for Hospitalisation for heart failure and CV death Data from
Slide 8: Novo Nordisk unlocked the market with Wegovy and reached the commercial aspiration
8 Obesity care Commercial execution and innovation Novo Nordisk® Novo Nordisk unlocked the market with Wegovy® and reached the commercial strategic aspiration for obesity Obesity care sales development The aspiration was reached in 2023 DKK billion 50 Commercial 42 execution 40 10 30 ✓ More than 25
Slide 9: Since the Wegovy launch in 2021 the large unmet need in obesity remains
9 Obesity care Commercial execution and innovation Novo Nordisk® With the launch of Wegovy® in 2021 a lot changed yet the large unmet need in obesity remains Few people are treated for obesity today Key market changes since the Wegovy® launch in 2021 Million people Patients Prescribers Payers 1,000
Slide 10: Strategy focuses on addressing the unmet need with innovative treatments
10 Obesity care Commercial execution and innovation Novo Nordisk® Strategy focuses on addressing the unmet need in obesity with innovative treatments Strategy focuses on a differentiated product portfolio beyond weight loss alone Additional factors to be competitive Approved products Pipeline produc
Slide 11: Treating the SELECT population is up to twice as cost-effective
11 Obesity care Commercial execution and innovation Novo Nordisk® Treating the SELECT vs STEP 1 population with semaglutide 2.4 mg is up to twice as cost-effective Cost-effectiveness in the STEP 1 compared to the SELECT population SELECT is important to payers People living with obesity (PwO) The SE
Slide 12: The Wegovy launch in the US unlocked the obesity market
12 Obesity care Commercial execution and innovation Novo Nordisk® The Wegovy® launch in the US unlocked the obesity market despite supply constraints Wegovy® initiated the obesity market expansion in NAO Obesity care was the 2nd biggest contributor to NAO’s growth in 2023 DKK billion 1 50 178% +27 5
Slide 13: Broadening focus from weight loss to improving health for patients
13 Obesity care Commercial execution and innovation Novo Nordisk® Novo Nordisk is broadening focus from solely weight loss to improving health for patients with overweight or obesity Patient persistency on anti-obesity medications after 12 months Characteristics for patients on Wegovy® in the US Pat
Slide 14: Wegovy launch drove increased number of prescribers
14 Obesity care Commercial execution and innovation Novo Nordisk® The launch of Wegovy® drove increased number of prescribers, but still lags diabetes products More doctors write prescriptions for AOMs Wegovy® has many new prescribers HCP engagement is still relevant Number of prescribers (000’s) 1,
Slide 15: Expanded affordable care access to Wegovy to ~50 million people
15 Obesity care Commercial execution and innovation Novo Nordisk® Novo Nordisk has expanded affordable care access to Wegovy® to ~50 million people and SELECT is set to help improve it ~50m people have Wegovy® coverage in the US Progress across all channels in 2023 People with obesity (millions) Com
Slide 16: Wegovy launches in International Operations show demand beyond the US
16 Obesity care Commercial execution and innovation Novo Nordisk® Despite supply constraints, the Wegovy® launches in IO has shown that the demand is not only a US phenomenon Wegovy® performance underlines the unmet need in IO Wegovy® launched in 8 International Operations markets DKK billion 10 Den
Slide 17: Unmet need in Denmark underlined by Wegovy penetration rate
17 Obesity care Commercial execution and innovation Novo Nordisk® The unmet need in Denmark is underlined by Wegovy® penetration rate of 7% in the obese population Wegovy® penetration rate in Denmark since launch Characteristics for patients on Wegovy® in Denmark TRx (000’) 71% female 100 1% 7% Most
Slide 18: Anti-obesity medications mostly out-of-pocket, with SELECT as key lever
18 Obesity care Commercial execution and innovation Novo Nordisk® Anti-obesity medications are expected to be mostly out-of- pocket, with SELECT as key lever to improve reimbursement Majority of IO AOM sales are currently OOP Current AOM reimbursement examples SELECT could improve access to Wegovy®
Slide 19: Continuing development of a portfolio of superior treatment solutions for obesity
19 Obesity care Commercial execution and innovation Novo Nordisk® Novo Nordisk is continuing the development of a portfolio of superior treatment solutions for obesity Building a leading portfolio Development pipeline 2024 2025 2026 2027 Our key focus areas SELECT, sema 2.4 mg, CVOT Regulatory decis
Slide 20: Semaglutide 2.4 mg improved pain and physical function in STEP 9
20 Obesity care Commercial execution and innovation Novo Nordisk® Semaglutide 2.4 mg showed a clinically meaningful improvement in OA patients’ pain and physical function in the STEP 9 trial Key highlights of the STEP 9 trial Superior improvement in WOMAC pain score with semaglutide 2.4 mg Mean base
Slide 21: Comprehensive phase 3 programme in obesity with CagriSema
21 Obesity care Commercial execution and innovation Novo Nordisk® We are planning a comprehensive phase 3 programme in Obesity with CagriSema including several outcome trials Ongoing CagriSema phase 3 development programme Potential future trials within obesity • 3,400 participants Phase 3 developme
Slide 22: Monlunabant (INV-202) oral CB1R inverse agonist showing weight loss potential
22 Obesity care Commercial execution and innovation Novo Nordisk® Monlunabant (INV-202) is an oral small molecule CB1R inverse agonist showing weight loss potential in phase 1 INV-202 showed mean weight reduction of -3.5kg at day 28 Highlights of the monlunabant (INV-202) trial Mean baseline body we
Slide 23: Oral amycretin phase 1 completed, subcutaneous phase 1 ongoing
23 Obesity care Commercial execution and innovation Novo Nordisk® Oral amycretin phase 1 trial completed and subcutaneous amycretin phase 1 trial ongoing with expected read-out in 2025 Results from oral amycretin phase 1 on weight loss Amycretin development programme in obesity Mean baseline body we
Slide 24: Closing remarks
Novo Nordisk® Closing remarks Wegovy® has unlocked the obesity care market yet a large unmet need remains SELECT trial is a key differentiator with semaglutide 2.4 mg as the first and only AOM treatment with a proven CV benefit Pipeline and supply capacity support continued leadership in obesity ABI